Hence, SSAs are now used as a treatment option for patients with progressive well-differentiated pancreatic and midgut NENs, preferably with a Ki-67 of ≤10%, regardless of the functional status of the tumour, to either prevent or inhibit tumour growth [158]. The gene discussed is MKI67; the disease is neoplasm.